Shire Receives EU’s MAA for VEYVONDI for the Treatment of

Shots: Approval is based on three clinical trials (N=80) assessing safety, tolerability, PK, haemostatic efficacy of rVWF in adults: P-III for rFVIII with severe VWD; P-III for rFVIII and rVWF in the treatment of bleeding episodes with severe VWD; P-III with severe VWD undergoing major/ minor/oral elective surgical procedures (w/o rFVIII) VEYVONDI [vonicog alfa, recombinant […]Read More